P57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene

Genes and Development

Volumn 9, Issue 6, 1995, Pages 650-662

  Matsuoka, Shuhei ^a   Edwards, Michael C ^a   Bai, Chang ^a   Parker, Susan ^a   Zhang, Pumin ^a   Baldini, Antonio ^a   Harper, J Wade ^a   Elledge, Stephen J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cdk inhibitor; Cell cycle; p21CIP1; p57KIP2; Tumor suppressor

Indexed keywords

CDK2 PROTEIN; CIP1 PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASES; CYCLIN KINASE INHIBITOR PROTEIN 2; CYCLINE; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASES; RECOMBINANT PROTEIN; ALANINE; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR; ENZYME INHIBITOR; MESSENGER RNA; PROLINE; PROTEIN P21; PROTEIN P57; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CHROMOSOME 11; CHROMOSOME MAP; EMBRYOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; KARYOTYPING; METABOLISM; MOLECULAR GENETICS; MOUSE; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROTEIN BINDING; SEQUENCE HOMOLOGY; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR GENE; ANIMAL TISSUE; BECKWITH WIEDEMANN SYNDROME; CARCINOGENESIS; CHROMOSOME 11P; EMBRYO DEVELOPMENT; GENE EXPRESSION; HUMAN TISSUE; IN SITU HYBRIDIZATION; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TISSUE SPECIFICITY;

AMINO ACID SEQUENCE; ANIMAL; BASE SEQUENCE; CELL CYCLE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 11; CYCLIN-DEPENDENT KINASES; CYCLINS; G1 PHASE; GENES, TUMOR SUPPRESSOR; HUMAN; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MICE; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TISSUE DISTRIBUTION; TRANSCRIPTION, GENETIC;

ANIMALIA;

EID: 0028988159     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.9.6.650     Document Type: Article

References (50)

1. Bai, C., R. Richman, and S.J. Elledge. 1994. Human cyclin F. EMBO J. 13: 6087-6098.
2. Cairns, P., L. Mao, A. Merlo, D. Lee, D. Schwab, Y. Eby, K. Tokino, P. Van Der Riet, J. Blaugrund, D. Sidransky, A. Kamb, Q. Liu, K. Harshman, S. Tavtigian, C. Cordon-Cardo, and M. Skolnick. 1994. Rates of p 16[MTS1] mutations in primary tumors with p9 loss. Science 265: 415-417.
3. Draetta, G. 1993. cdc2 activation: The interplay of cyclin binding and Thr161 phosphorylation. Trends Cell Biol. 3: 287-289.
4. Dulic, V., W.K. Kaufman, S. Wilson, T.D. Tlsty, E. Lees, J.W. Harper, S.J. Elledge, and S.I. Reed. 1994. p53-dependent inhibition of cyclin dependent kinase activitites in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023.
5. Durfee, T., K. Becherer, P.-L. Chen, S.-H. Yeh, Y. Yang, A. Kilburn, W.-H. Lee, and S.J. Elledge. 1993. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Genes &. Dev. 7: 555-569.
6. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
7. El-Deiry, W.S., J.W. Harper, P.M. O'Connor, V. Velculescu, C.E. Canman, J. Jackman, J. Pietenpol, M. Burrell, D.E. Hill, K.G. Wiman, W.E. Mercer, M.B. Kastan, K.W. Kohn, S.J. Elledge, K.W. Kinzler, and B. Vogelstein. 1994. WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res. 54: 1169-1174.
8. Elledge, S.J. and R.W. Davis. 1990. Two gene differentially regulated in the cell cycle and by DNA-damaging agents encode alternative regulatory subunits in ribonucleotide reductase. Genes & Dev. 4: 740-751.
9. Elledge, S.J. and J.W. Harper. 1994. Cdk Inhibitors: On the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6: 874-878.
10. Elledge, S.J., R. Richman, F.L. Hall, R.T. Williams, N. Logsdon, and J.W. Harper. 1992. CDK2 encodes a 33 kd cyclin A-associated protein kinase and is expressed before CDC2 in the cell cycle. Proc. Natl. Acad. Sci. 89: 2907-2911.
11. Flores-Rozas, H., Z. Kelman, F. Dean, Z.-Q. Pan, J.W. Harper, S.J. Elledge, M. O'Donnell, and J. Hurwitz. 1994. Cdk-interacting protein-1 (Cip1, Waf1) directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc. Natl. Acad. Sci. 91: 8655-8659.
12. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes & Dev. 8: 2939-2952.
13. Halevy, O., B.G. Novitch, D.B. Spicer, S.X. Skapek, J. Rhee, G.J. Hannon, D. Beach, and A. Lassar. 1995. Terminal cell cycle arrest of skeletal muscle correslates with induction of p21 by MyoD. Science (in press).
14. INK4B is a potential effector of TGF-β induced cell cycle arrest. Nature 371: 257-261.
15. Harlow, E. and D. Lane. 1988. Antibodies: A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
16. Harper, J.W., G. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The 21 kd Cdk interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
17. Harper, J.W., S.J. Elledge, K. Keyomarsi, B. Dynlacht, L.-H. Bai, P. Zhang, S. Dobrowoski, C. Bai, L. Connell-Growley, E. Swindell, M.P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell (in press).
18. Hastie, N.D. 1994. The Genetics of Wilm's tumor. A case of disrupted development. Annu. Rev. Genet. 28: 523-558.
19. Hinds, P.W., S. Mittnacht, V. Dulic, A. Arnold, S.I. Reed, and R.A. Weinberg. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70: 993-1006.
20. Ijdo, J.W., E.A. Lindsay, R.A. Wells, and A. Baldini. 1992. Multiple variants in subtelomeric regions of normal karyotypes. Genomics 14: 1019-1025.
21. Jen, J., J.W. Harper, S.H. Bigner, D.D. Bigner, N. Papadopoulos, S. Markowitz, J.K.V. Willson, K.W. Kinzler, and B. Vogelstein. 1994. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54: 6353-6358.
22. Jiang, H., J. Lin, Z.-Z. Su, F.R. Collart, E. Huberman, and P.B. Fisher. 1994. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21 WAF/CIP1, expression in the absence of p53. Oncogene 9: 3397-3407.
23. Iunien, C. 1992. Beckwith-Wiedemann Syndrome, tumourigenesis and imprinting. Curr. Opin. Genet. Dev. 2: 431-438.
24. Kamb, A., N.A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S.V. Tavtigan, E. Stockert, R.S.I. Day, R.E. Johnson, and M.H. Skolnick. 1994. A cell cycle regulator potentially involved in the genesis of many tumor types. Science 264: 436-440.
25. KIP1) of cyclin-dependent kinase 4 activation. Cell 79: 487-496.
26. Martinez, J., I. Georgoff, J. Martinez, and A.J. Levine. 1991. Cellular localization and cell cycle regulation by a temperature-sensitive p53-protein. Genes & Dev. 5:152-159.
27. PSK- J3/cdk4) for mammalian D-type G1 cyclins. Cell 71: 323-334.
28. Meyerson, M. and E. Harlow. 1994. Identification of G1 kinase activity for Cdk6, a novel cyclin D partner. Mol. Cell Biol. 14: 2077-2086.
29. Michieli, P., M. Chedid, D. Lin, J.H. Pierce, W.E. Mercer, and D. Givol. 1994. Induction of WAF1/CIP1/ by a p53-independent pathway. Cancer Res. 54: 3391-3395.
30. Nobori, T., K. Miura, D.J. Wu, A. Lois, K. Takabayashi, and D.A. Carson. 1994. Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756.
31. Noda, A., Y. Ning, S.F. Venable, O.M. Pereira-Smith, and J.R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression cloning screen. Exp. Cell Res. 211: 90-98.
32. KIP1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573.
33. Cip1 in muscle and other terminally differentiating cells. Science 267: 1024-1027.
34. Pettenati, M.J., J.L. Haines, R.R. Higgins, R.S. Wappner, C.G. Palmer, and D. Weaver. 1986. Beckwith-Wiedemann syndrome: Presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum. Genet. 74: 143-154.
35. Pines, J. 1993. Cyclins and cyclin-dependent kinases: Take your partners. Trends Biochem. Sci. 18: 195-197.
36. KIP1, a cyclin-dependent kinase inhibitor and potential mediator of extracellular antimitogenic signals. Cell 78: 59-66.
37. Seizinger, B., H.P. Klinger, C. Junien, Y. Nakamura, M. Le Beau, W. Cavenee, B. Amanuel, B. Ponder, S. Naylor, F. Mittelman, D. Louis, A. Menon, I. Newsham, J. Decker, M. Kaelbling, I. Henry, and A.V. Deimling. 1991. Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet. Cell. Genet. 58: 1080-1096.
38. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
39. Sheikh, M.S., X. Li, J. Chen, Z. Shao, J.V. Ordonez, and J.A. Fontana. 1994. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407-3415.
40. Sherr, C.J. 1994. G1 phase progression: Cycling on cue. Cell 79: 551-555.
41. Solomon, M.J. 1993. Activation of the various cyclin/cdc2 protein kinases. Curr. Opin. Cell Biol. 5: 180-186.
42. Spruck, C.H., M. Gonzalez-Zulueta, A. Shibata, A.R. Simoneau, M.F. Lin, F. Gonzales, Y.C. Tsai, and P. Jones. 1994. p16 gene in uncultured tumours. Nature 370: 183-184.
43. Steinman, R.A., B. Hoffman, A. Iro, C. Guillouf, D.A. Liebermann, and M.E. El-Houseini. 1994. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 9: 3389-3396.
44. Toyoshima, H. and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74.
45. van der Heuvel, S. and E. Harlow. 1993. Distinct roles for cyclindependent kinases in cell cycle control. Science 26: 2050-2054.
46. Waga, S., G.J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin- dependent kinases controls DNA replication by interacting with PCNA. Nature 369: 574-578.
47. Wiedemann, H.R. 1983. Tumours and hemihypertrophy associated with Wiedemann-Beckwith syndrome. Eur. J. Pediatr. 141: 129.
48. Xiong, Y., G. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
49. Zhang, H., G. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes & Dev. 8: 1750-1758.
50. Zhu, L., S. Heuvel, K. Helin, A. Fattaey, M. Ewen, D. Livingston, N. Dyson, and E. Harlow. 1993. Inhibition of cell proliferation by p 107, a relative of the retinoblastoma protein. Genes & Dev. 7: 1111-1125.